In mice with ARID1A‐deficient ovarian cancer, the therapeutic effect of PD‐L1 inhibitors was greatly enhanced, suggesting ICI treatment could be beneficial for ARID1A‐impaired patients.11 The gene discussed is ARID1A; the disease is ovarian cancer.